Insider BFI Co. linked to CEO converts and sells PAHC shares
Rhea-AI Filing Summary
Phibro Animal Health insider activity shows trades by major shareholder BFI Co., LLC, an entity over which President and CEO Jack Bendheim has voting and dispositive power. On January 23, 2026, BFI sold 1,235 shares of Class A Common Stock at a weighted average price of $40.5538 per share under a Rule 10b5-1 trading plan adopted on May 30, 2025. On January 26, 2026, BFI converted 30,000 shares of Class B Common Stock into Class A Common Stock on a one-for-one basis at an exercise price of $0. Following these transactions, BFI indirectly held 45,445 Class A shares, while Jack Bendheim also directly held 16,840 Class A shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 30,000 | $0.00 | -- |
| Conversion | Class A Common Stock | 30,000 | $0.00 | -- |
| Sale | Class A Common Stock | 1,235 | $40.5538 | $50K |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (1)
- The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.175 to $41.01. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. The reported securities are directly held by Jack Bendheim.
FAQ
What insider transactions were reported in Phibro Animal Health (PAHC) Form 4?
The filing reports that BFI Co., LLC sold 1,235 Class A shares at a weighted average price of $40.5538 on January 23, 2026, and converted 30,000 Class B shares into Class A shares on January 26, 2026.
Who is BFI Co., LLC in relation to Phibro Animal Health (PAHC)?
BFI Co., LLC is a 10% owner of Phibro Animal Health. President and CEO Jack Bendheim exercises voting and dispositive power over BFI and may be deemed to share voting and investment power over BFI-held securities.
Was the Phibro Animal Health (PAHC) insider sale part of a 10b5-1 trading plan?
Yes. The 1,235-share sale of Class A stock by BFI on January 23, 2026 was executed under a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.
What is the relationship of Jack Bendheim to Phibro Animal Health (PAHC)?
Jack Bendheim is a director, President and CEO, and a 10% owner of Phibro Animal Health. He has voting and dispositive power over BFI Co., LLC and directly holds additional Class A shares.
How does the Class B to Class A conversion work for Phibro Animal Health (PAHC)?
The filing states that Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis at the holder’s election and has no expiration date.